Sitagliptin for the prevention of stress hyperglycemia in patients without diabetes undergoing coronary artery bypass graft (CABG) surgery
Aims To determine if treatment with sitagliptin, a dipeptidyl peptidase-4 inhibitor, can prevent stress hyperglycemia in patients without diabetes undergoing coronary artery bypass graft (CABG) surgery.Methods We conducted a pilot, double-blinded, placebo-controlled randomized trial in adults (18–80...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2019-05-01
|
| Series: | BMJ Open Diabetes Research & Care |
| Online Access: | https://drc.bmj.com/content/7/1/e000703.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850256124118302720 |
|---|---|
| author | Saumeth Cardona Priyathama Vellanki Maya Fayfman Rodolfo J Galindo Francisco J Pasquel Katerina Tsegka Limin Peng Sol Jacobs Michael Halkos Robert A Guyton Vinod H Thourani Guillermo Umpierrez |
| author_facet | Saumeth Cardona Priyathama Vellanki Maya Fayfman Rodolfo J Galindo Francisco J Pasquel Katerina Tsegka Limin Peng Sol Jacobs Michael Halkos Robert A Guyton Vinod H Thourani Guillermo Umpierrez |
| author_sort | Saumeth Cardona |
| collection | DOAJ |
| description | Aims To determine if treatment with sitagliptin, a dipeptidyl peptidase-4 inhibitor, can prevent stress hyperglycemia in patients without diabetes undergoing coronary artery bypass graft (CABG) surgery.Methods We conducted a pilot, double-blinded, placebo-controlled randomized trial in adults (18–80 years) without history of diabetes. Participants received sitagliptin or placebo once daily, starting the day prior to surgery and continued for up to 10 days. Primary outcome was differences in the frequency of stress hyperglycemia (blood glucose (BG) >180 mg/dL) after surgery among groups.Results We randomized 32 participants to receive sitagliptin and 28 to placebo (mean age 64±10 years and HbA1c: 5.6%±0.5%). Treatment with sitagliptin resulted in lower BG levels prior to surgery (101±mg/dL vs 107±13 mg/dL, p=0.01); however, there were no differences in the mean BG concentration, proportion of patients who developed stress hyperglycemia (21% vs 22%, p>0.99), length of hospital stay, rate of perioperative complications and need for insulin therapy in the intensive care unit or during the hospital stay.Conclusion The use of sitagliptin during the perioperative period did not prevent the development of stress hyperglycemia or need for insulin therapy in patients without diabetes undergoing CABG surgery. |
| format | Article |
| id | doaj-art-84fcff3743514cd6b09b39e428c2d33c |
| institution | OA Journals |
| issn | 2052-4897 |
| language | English |
| publishDate | 2019-05-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open Diabetes Research & Care |
| spelling | doaj-art-84fcff3743514cd6b09b39e428c2d33c2025-08-20T01:56:42ZengBMJ Publishing GroupBMJ Open Diabetes Research & Care2052-48972019-05-017110.1136/bmjdrc-2019-000703Sitagliptin for the prevention of stress hyperglycemia in patients without diabetes undergoing coronary artery bypass graft (CABG) surgerySaumeth Cardona0Priyathama Vellanki1Maya Fayfman2Rodolfo J Galindo3Francisco J Pasquel4Katerina Tsegka5Limin Peng6Sol Jacobs7Michael Halkos8Robert A Guyton9Vinod H Thourani10Guillermo Umpierrez11Medicine, Emory University School of Medicine, Atlanta, Georgia, USADepartent of Medicine, Emory University, Atlanta, Georgia, USAMedicine, Emory University School of Medicine, Atlanta, Georgia, USADivision of Endocrinology, Diabetes, and Metabolism, University of Miami Miller School of Medicine, Miami, Florida, USAMedicine, Emory University School of Medicine, Atlanta, Georgia, USAMedicine, Emory University School of Medicine, Atlanta, Georgia, USADepartent of Medicine, Emory University, Atlanta, Georgia, USAMedicine, Emory University School of Medicine, Atlanta, Georgia, USAThoracic Surgery, Emory University School of Medicine, Atlanta, Georgia, USAThoracic Surgery, Emory University School of Medicine, Atlanta, Georgia, USAThoracic Surgery, Emory University School of Medicine, Atlanta, Georgia, USADepartment of Medicine, Emory University, Atlanta, Georgia, USAAims To determine if treatment with sitagliptin, a dipeptidyl peptidase-4 inhibitor, can prevent stress hyperglycemia in patients without diabetes undergoing coronary artery bypass graft (CABG) surgery.Methods We conducted a pilot, double-blinded, placebo-controlled randomized trial in adults (18–80 years) without history of diabetes. Participants received sitagliptin or placebo once daily, starting the day prior to surgery and continued for up to 10 days. Primary outcome was differences in the frequency of stress hyperglycemia (blood glucose (BG) >180 mg/dL) after surgery among groups.Results We randomized 32 participants to receive sitagliptin and 28 to placebo (mean age 64±10 years and HbA1c: 5.6%±0.5%). Treatment with sitagliptin resulted in lower BG levels prior to surgery (101±mg/dL vs 107±13 mg/dL, p=0.01); however, there were no differences in the mean BG concentration, proportion of patients who developed stress hyperglycemia (21% vs 22%, p>0.99), length of hospital stay, rate of perioperative complications and need for insulin therapy in the intensive care unit or during the hospital stay.Conclusion The use of sitagliptin during the perioperative period did not prevent the development of stress hyperglycemia or need for insulin therapy in patients without diabetes undergoing CABG surgery.https://drc.bmj.com/content/7/1/e000703.full |
| spellingShingle | Saumeth Cardona Priyathama Vellanki Maya Fayfman Rodolfo J Galindo Francisco J Pasquel Katerina Tsegka Limin Peng Sol Jacobs Michael Halkos Robert A Guyton Vinod H Thourani Guillermo Umpierrez Sitagliptin for the prevention of stress hyperglycemia in patients without diabetes undergoing coronary artery bypass graft (CABG) surgery BMJ Open Diabetes Research & Care |
| title | Sitagliptin for the prevention of stress hyperglycemia in patients without diabetes undergoing coronary artery bypass graft (CABG) surgery |
| title_full | Sitagliptin for the prevention of stress hyperglycemia in patients without diabetes undergoing coronary artery bypass graft (CABG) surgery |
| title_fullStr | Sitagliptin for the prevention of stress hyperglycemia in patients without diabetes undergoing coronary artery bypass graft (CABG) surgery |
| title_full_unstemmed | Sitagliptin for the prevention of stress hyperglycemia in patients without diabetes undergoing coronary artery bypass graft (CABG) surgery |
| title_short | Sitagliptin for the prevention of stress hyperglycemia in patients without diabetes undergoing coronary artery bypass graft (CABG) surgery |
| title_sort | sitagliptin for the prevention of stress hyperglycemia in patients without diabetes undergoing coronary artery bypass graft cabg surgery |
| url | https://drc.bmj.com/content/7/1/e000703.full |
| work_keys_str_mv | AT saumethcardona sitagliptinforthepreventionofstresshyperglycemiainpatientswithoutdiabetesundergoingcoronaryarterybypassgraftcabgsurgery AT priyathamavellanki sitagliptinforthepreventionofstresshyperglycemiainpatientswithoutdiabetesundergoingcoronaryarterybypassgraftcabgsurgery AT mayafayfman sitagliptinforthepreventionofstresshyperglycemiainpatientswithoutdiabetesundergoingcoronaryarterybypassgraftcabgsurgery AT rodolfojgalindo sitagliptinforthepreventionofstresshyperglycemiainpatientswithoutdiabetesundergoingcoronaryarterybypassgraftcabgsurgery AT franciscojpasquel sitagliptinforthepreventionofstresshyperglycemiainpatientswithoutdiabetesundergoingcoronaryarterybypassgraftcabgsurgery AT katerinatsegka sitagliptinforthepreventionofstresshyperglycemiainpatientswithoutdiabetesundergoingcoronaryarterybypassgraftcabgsurgery AT liminpeng sitagliptinforthepreventionofstresshyperglycemiainpatientswithoutdiabetesundergoingcoronaryarterybypassgraftcabgsurgery AT soljacobs sitagliptinforthepreventionofstresshyperglycemiainpatientswithoutdiabetesundergoingcoronaryarterybypassgraftcabgsurgery AT michaelhalkos sitagliptinforthepreventionofstresshyperglycemiainpatientswithoutdiabetesundergoingcoronaryarterybypassgraftcabgsurgery AT robertaguyton sitagliptinforthepreventionofstresshyperglycemiainpatientswithoutdiabetesundergoingcoronaryarterybypassgraftcabgsurgery AT vinodhthourani sitagliptinforthepreventionofstresshyperglycemiainpatientswithoutdiabetesundergoingcoronaryarterybypassgraftcabgsurgery AT guillermoumpierrez sitagliptinforthepreventionofstresshyperglycemiainpatientswithoutdiabetesundergoingcoronaryarterybypassgraftcabgsurgery |